SCHEMBL23927505

SCHEMBL23927505

CCOC(=O)c1nnc(CC2CCCCCC2)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
ALDH1A1 P00352 6/20 0.40
TSHR P16473 3/20 0.40
KDM4E B2RXH2 5/20 0.39
HPGD P15428 4/20 0.39
HTT P42858 1/20 0.39
RECQL P46063 1/20 0.39
ADORA2A P29274 2/20 0.39
ADORA2B P29275 2/20 0.39
GAA P10253 3/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ADORA1 P30542 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17324360 1.00 LMNA (0.44) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL15964597 0.99 LMNA (0.42) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL22272515 0.96 KDM4E (0.40) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL22272514 0.93 KDM4E (0.42) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL22272516 0.86 TSHR (0.39) ALDH1A1TSHRKDM4EHPGDHTT
SCHEMBL17324357 0.84 LMNA (0.41) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL17324406 0.84 LMNA (0.35) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL22272519 0.84 KDM4E (0.36) LMNAALDH1A1TSHRKDM4EHPGD
SCHEMBL15964621 0.79 KDM5B (0.41) ADORA2AADORA2BADORA1
SCHEMBL22048751 0.78 ADORA2A (0.34) ALDH1A1ADORA2AADORA2BADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 LMNA 2659/4885ALDH1A1 4164/4885TSHR 2607/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 LMNA 2659/4885ALDH1A1 4164/4885TSHR 2607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.